Trial · NCT04676724
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Treatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 9 | Percentage of Participants | ||
| Treatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 15 | Percentage of Participants | ||
| Treatment Arm 1: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ) | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | End of treatment (up to 48 weeks) | 15 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ) | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 13 | Percentage of Participants | |
| Treatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | End of treatment (up to 36 weeks) | 15 | Percentage of Participants | |
| Treatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | Up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) | 17 | Percentage of Participants | |
| Treatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ) | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | Up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | 15 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg <LLOQ - End of Treatment (up to 48 weeks) | 18 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg<LLOQ - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 13 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline <0.5 - End of Treatment (up to 48 weeks) | 24 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline <0.5- Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 45 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline >=0.5 - End of Treatment (up to 48 weeks) | 42 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline >=0.5 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 44 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline >=1 - End of Treatment (up to 48 weeks) | 33 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline >=1- Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 36 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline >=1.5 - End of Treatment (up to 48 weeks) | 27 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline >=1.5 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 36 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline >=3 - End of Treatment (up to 48 weeks) | 20 | Percentage of Participants | |
| Treatment Arm 1: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg decline >=3 - Up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | 27 | Percentage of Participants | |
| Treatment Arm 2: Percentage of Participants With Categorical Changes From Baseline in HBsAg Values | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | HBsAg <LLOQ - End of Treatment (up to 36 weeks) | 15 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04676724/results